Protective pan-ebolavirus combination therapy by two multifunctional human antibodies
Pavlo Gilchuk(AstraZeneca (Japan)), James E. Crowe(Vanderbilt University Medical Center), Rachel E. Sutton(Vanderbilt University Medical Center), Krystle N. Agans(Galveston College), Natalia A. Kuzmina(Galveston College), Kai Huang(Galveston College), Philipp A. Ilinykh(Houston Methodist), Robert W. Cross(The University of Texas Medical Branch at Galveston), Rachel S. Nargi(Vanderbilt University Medical Center), Viktoriya Borisevich(Galveston College), Naveenchandra Suryadevara(Vanderbilt University), Robin Bombardi(Vanderbilt University Medical Center), Thomas W. Geisbert(The University of Texas Medical Branch at Galveston), Charles D. Murin(Scripps Research Institute), Andrew B. Ward(Scripps Research Institute), Seth J. Zost(Vanderbilt University Medical Center), Robert H. Carnahan(Vanderbilt University Medical Center), Joan B. Geisbert(The University of Texas Medical Branch at Galveston), Alexander Bukreyev(Galveston College)
Cited by 2
Related Papers
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
|Proceedings of the National Academy of Sciences|2017|1.2k
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
|Cell Host & Microbe|2020|1.2k
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors
|Nature Communications|2019|948